MedPath

The Comparative Study on the Effect of Ilaprazole and Esomeprazole for Laryngopharyngeal Reflux

Not Applicable
Completed
Conditions
Diseases of the respiratory system
Registration Number
KCT0006492
Lead Sponsor
Dong-A University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
50
Inclusion Criteria

1) Male or female over 19 years of age and under 70 years of age
2) Laryngeal reflux (LPR) patients with reflux observation score (RFS) of 7 or more and reflux symptom index (RSI) of 13 or more
character
3) Those who agreed to participate in this study and voluntarily signed the written consent
4) Those without dementia or cognitive impairment

Exclusion Criteria

1) Those with a history of allergic symptoms (rash, fever, itching, etc.) or hypersensitivity reactions to this research drug
2) Those with confirmed malignant tumor or infection of the larynx
3) Those taking Atazanavir or Rilpivirine
4) 3 months of study participation with another proton pump inhibitor (PPI) or H2 receptor aatagonist (H2RA)
those who took it within
5) Those with a history of Zollinger-Ellison syndrome (ZES), alcoholism, or substance abuse
6) Pregnant and lactating women
7) Those who have participated in a clinical trial within 6 months of participating in the study
8) Those who are judged inappropriate by the researcher to participate in the research for other reasons

Study & Design

Study Type
Observational Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Comparison of improvement in the reflux symptom index (RSI) of the ilaprazole group and the esomeprazole group
Secondary Outcome Measures
NameTimeMethod
Comparison of the improvement in the reflux findings score (RFS) between the ilaprazole group and the esomeprazole group
© Copyright 2025. All Rights Reserved by MedPath